• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

检测结核分枝杆菌对新药敏感性的能力有限。

Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs.

作者信息

Farooq Hamzah Z, Cirillo Daniela M, Hillemann Doris, Wyllie David, van der Werf Marieke J, Ködmön Csaba, Nikolayevskyy Vlad

出版信息

Emerg Infect Dis. 2021 Mar;27(3):985-987. doi: 10.3201/eid2703.204418.

DOI:10.3201/eid2703.204418
PMID:33622487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7920658/
Abstract

We surveyed availability of phenotypic drug susceptibility testing for drug-resistant Mycobacterium tuberculosis in Europe. Of 27 laboratories, 17 tested for linezolid, 11 for clofazimine, 9 for bedaquiline, and 6 for delamanid during 2019. Our findings indicate that testing capacity for newer and repurposed tuberculosis drugs exists, but its availability is limited.

摘要

我们调查了欧洲耐药结核分枝杆菌的表型药敏试验的可及性。在27个实验室中，2019年有17个实验室开展了利奈唑胺检测，11个开展了氯法齐明检测，9个开展了贝达喹啉检测，6个开展了德拉马尼检测。我们的研究结果表明，对于新型和重新利用的结核病药物存在检测能力，但可及性有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd1b/7920658/36182581fd0d/20-4418-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd1b/7920658/36182581fd0d/20-4418-F.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd1b/7920658/36182581fd0d/20-4418-F.jpg

相似文献

1
Limited Capability for Testing Mycobacterium tuberculosis for Susceptibility to New Drugs.检测结核分枝杆菌对新药敏感性的能力有限。
Emerg Infect Dis. 2021 Mar;27(3):985-987. doi: 10.3201/eid2703.204418.
2
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.新型和重新定位的抗结核分枝杆菌药物贝达喹啉、氯法齐明、利奈唑胺、德拉马尼和普托马尼耐药相关突变的系统评价。
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.
3
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.结核分枝杆菌复合体临床分离株中新药和再利用药物表型耐药相关的基因组突变及其相关性研究。
J Antimicrob Chemother. 2023 Nov 6;78(11):2637-2644. doi: 10.1093/jac/dkad252.
4
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.中国耐贝达喹啉和德拉马尼的结核分枝杆菌流行率。
J Glob Antimicrob Resist. 2021 Sep;26:241-248. doi: 10.1016/j.jgar.2021.06.007. Epub 2021 Jun 30.
5
Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.韩国耐多药和广泛耐药结核病中德拉马尼、贝达喹啉和利奈唑胺最低抑菌浓度分布及耐药相关基因突变。
Ann Lab Med. 2018 Nov;38(6):563-568. doi: 10.3343/alm.2018.38.6.563.
6
Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.验证一种包含贝达喹啉和德拉马尼的 14 药物微量滴定板，用于大规模结核分枝杆菌研究药敏试验。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00344-18. Print 2018 Sep.
7
Availability and costs of medicines for the treatment of tuberculosis in Europe.欧洲治疗结核病药物的可及性和成本。
Clin Microbiol Infect. 2023 Jan;29(1):77-84. doi: 10.1016/j.cmi.2022.07.026. Epub 2022 Aug 10.
8
atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.结核分枝杆菌 atpE 突变并不总是预示贝达喹啉治疗失败。
Emerg Infect Dis. 2022 May;28(5):1062-1064. doi: 10.3201/eid2805.212517.
9
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.耐多药结核病患者分离株中对氯法齐明和贝达喹啉的原发性耐药情况。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
10
Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.在耐多药结核病治疗期间低水平地奈达胺和贝达喹啉耐药的出现。
Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.

引用本文的文献

1
Strategies to Enhance Diagnostic Capabilities for the New Drug-Resistant Tuberculosis (DR-TB) Drugs.提高新型耐多药结核病（DR-TB）药物诊断能力的策略。
Pathogens. 2024 Nov 28;13(12):1045. doi: 10.3390/pathogens13121045.
2
Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan.乌兹别克斯坦卡拉卡尔帕克斯坦的耐多药结核病及相关危险因素
IJTLD Open. 2024 Sep 1;1(9):391-397. doi: 10.5588/ijtldopen.24.0351. eCollection 2024 Sep.
3
Combating antimicrobial resistance in malaria, HIV and tuberculosis.抗疟疾、艾滋病毒和结核病中的抗菌药物耐药性

本文引用的文献

1
Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study.贝达喹啉表型药敏试验方法及断点的验证：一项多实验室、多国研究。
J Clin Microbiol. 2020 Mar 25;58(4). doi: 10.1128/JCM.01677-19.
2
A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.英国耐多药结核病中阿米卡星治疗与贝达喹啉的成本比较。
J Infect. 2020 Jan;80(1):38-41. doi: 10.1016/j.jinf.2019.09.006. Epub 2019 Sep 21.
3
'Those who cannot remember the past are condemned to repeat it': Drug-susceptibility testing for bedaquiline and delamanid.
Nat Rev Drug Discov. 2024 Jun;23(6):461-479. doi: 10.1038/s41573-024-00933-4. Epub 2024 May 15.
4
Novel six-month all oral treatment of pre-extensively drug-resistant tuberculosis in Canada: New treatment options present new implementation challenges.加拿大新型六个月全口服治疗广泛耐药前结核病：新的治疗方案带来新的实施挑战。
Can Commun Dis Rep. 2023 Jan 5;49(1):15-20. doi: 10.14745/ccdr.v49i01a04.
5
The value of lung ultrasound score in neonatal respiratory distress syndrome: a prospective diagnostic cohort study.肺部超声评分在新生儿呼吸窘迫综合征中的价值：一项前瞻性诊断队列研究。
Front Med (Lausanne). 2024 Feb 8;11:1357944. doi: 10.3389/fmed.2024.1357944. eCollection 2024.
6
Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid.对贝达喹啉、利奈唑胺和普瑞马尼德的基线耐药性与获得性耐药性，以及在四项包含普瑞马尼德的结核病临床试验中对治疗结果的影响
PLOS Glob Public Health. 2023 Oct 18;3(10):e0002283. doi: 10.1371/journal.pgph.0002283. eCollection 2023.
7
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.结核分枝杆菌复合体临床分离株中新药和再利用药物表型耐药相关的基因组突变及其相关性研究。
J Antimicrob Chemother. 2023 Nov 6;78(11):2637-2644. doi: 10.1093/jac/dkad252.
8
Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians.一名青少年耐多药结核病（MDR-TB）患者对贝达喹啉（BDQ）耐药：给儿科医生的警示
IDCases. 2023 Aug 29;34:e01880. doi: 10.1016/j.idcr.2023.e01880. eCollection 2023.
9
Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres.更新世界卫生组织外周中心下一代结核分枝杆菌药物敏感性检测的目标产品简介。
PLOS Glob Public Health. 2023 Mar 31;3(3):e0001754. doi: 10.1371/journal.pgph.0001754. eCollection 2023.
10
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.结核分枝杆菌分子药物耐药检测的临床意义：2023 年 TBnet/RESIST-TB 共识声明。
Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28.
“那些不能从历史中吸取教训的人注定要重蹈覆辙”：贝达喹啉和德拉马尼的药敏试验。
Int J Infect Dis. 2019 Mar;80S:S32-S35. doi: 10.1016/j.ijid.2019.02.027. Epub 2019 Feb 25.
4
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.基于 DNA 测序的一线抗结核药物敏感性预测。
N Engl J Med. 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26.
5
Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope.治疗耐多药结核病的更短、更廉价方案：新希望
Indian J Med Res. 2017 Sep;146(3):301-303. doi: 10.4103/ijmr.IJMR_1704_16.
6
Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.结核分枝杆菌耐药性检测：挑战、最新进展与展望。
Clin Microbiol Infect. 2017 Mar;23(3):154-160. doi: 10.1016/j.cmi.2016.10.022. Epub 2016 Nov 1.
7
External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study.欧盟结核病诊断与耐药性的外部质量评估：一项为期五年的多中心实施研究
PLoS One. 2016 Apr 7;11(4):e0152926. doi: 10.1371/journal.pone.0152926. eCollection 2016.
8
Diagnosis of tuberculosis and drug resistance: what can new tools bring us?结核病与耐药性诊断：新工具能为我们带来什么？
Int J Tuberc Lung Dis. 2012 Jul;16(7):860-70. doi: 10.5588/ijtld.12.0180.